tasis. The 1-and 5-year post-hepatic transplantation survival rates among patients subjected to bone scintigraphy were 81% and 69%, respectively; those among patients not subjected to scintigraphy were 78% and 62%, respectively (p = 0.25). The 1-and 5-year post-HTx recurrence rates among patients subjected to bone scintigraphy were 4.8% and 10.7%; those among patients not subjected to scintigraphy were 2.9% and 10.1%, respectively (p = 0.46). Results: The cost generated by the current evaluation policies, US$ 27.582, did not result in the detection of any sub-clinical metastasis and therefore failed to provide positive cost-effectiveness. ConClusions: Clinical evidence has demonstrated that bone scintigraphy did not provide aditional information about patient selection since the incidence of metastasis in early stages is very low. In our cohort, the use of scintigraphy in the assessment of patients with early stages of HCC and within the Milão criteria, included in a liver transplant list by dead donor, in a center in the south of Brazil, had zero benefit. objeCtives: To determine the cost-utility of continuing education for the management of patients with type 2 Diabetes Mellitus (T2DM), in Pernambuco -Brazil. Methods: It's a cost-utility evaluation, using the Markov model to simulate the results in health scenarios, from the perspective of the health system. It was considered an analytic horizon of 20 years and selected the category of direct medical costs. Data were obtained from primary source, SERVIDIAH study, and secondary sources from health information systems and literature. The reference scenario represents the standard health care management performed in public health services. The simulated scenarios for post-intervention's results were based on the suggestion of consulted experts in regard the effectiveness of continuing education for health professionals in primary health care (PHC) for the patient's complications reduction. Results: The average individual, representative Pernambuco's population, was female, 61 years old and diagnosed with T2DM for 8.7 years. These and other clinical characteristics that influence the calculation of the transition probabilities were gathered from over 800 patients with T2DM from Pernambuco.
objeCtives: To critically appraise published pharmacoeconomic studies of two novel antiplatelet (AP) agents (ticagrelor and prasugrel) in the treatment of acute coronary syndromes (ACS). Methods: Key terms related to economic evaluations of ticagrelor and/or prasugrel were searched in EMBASE, MEDLINE and International Pharmaceutical Abstracts. English-language articles evaluating the use of these agents in adults with ACS were included. Studies assessing genotyping-guided treatments were excluded. Elements of each study were independently extracted based on the ISPOR Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist by two reviewers. Results: Eleven (7 ticagrelor, 4 prasugrel) studies were identified, 7 of which included both cost-effectiveness and cost-utility analysis. No comparisons were made between prasugrel and ticagrelor and each agent was compared to clopidogrel. The manufacturer of the novel AP funded all but one study. Most models were Markov-based simulations, with almost all studies adopting a healthcare system perspective and lifetime time horizon. Two randomized-control trials (RCTs), PLATO and TRITON-TIMI 38 were most commonly cited for ticagrelor and prasugrel, respectively, with few non-RCTs used for clinical data input. While methods to derive the efficacy data were commonly reported, utility estimates varied for some health states between studies using the same data by the same sponsor. Both ticagrelor and prasugrel were deemed cost-effective vs. clopidogrel in base-case analyses. ConClusions: Studies would benefit from greater consistency in sources of costing data and estimates of utility values and decrements. There is a clear reliance on single multinational RCTs as the primary data source for the vast majority of model inputs, and the PLATO study has been heavily criticized for issues related to external validity. More independent, non-industry sponsored economic evaluations and real-world clinical data are required in the future. Reporting checklists do not capture these latent issues behind economic evaluations, as identified by our appraisal of the literature.
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further investigation as a way to detect, characterize, and address bias in retrospective samples.
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MEtastatiC-fREE sURvival and ovERall sURvival in PRostatE CanCER
Li T. 1 , Thompson M. 2 , Tran D. 2 1 Janssen Global Services, Raritan, NJ, USA, 2 Cornerstone Research Group, Burlington, ON, Canada objeCtives: In clinical trials of early-stage prostate cancer, demonstration of an overall survival (OS) benefit is challenging because of prolonged patient survival. While the development of metastasis is a major milestone in the disease, payers are interested in understanding the clinical relevance of metastatic-free survival (MFS) as a surrogate endpoint and its relationship with long-term outcomes, in particular, OS. The objective of the current study was to identify empirical evidence evaluating MFS in patients with prostate cancer. Methods: A structured literature review was conducted in PubMed (1999 PubMed ( −2014 to identify clinical trials in prostate cancer using MFS as a primary endpoint, and clinical and observational studies that evaluated the association between MFS and OS. Results: Three published clinical trials used MFS as a primary endpoint. The studies employed varying definitions for MFS (e.g., bone metastasis only or bone and soft tissue metastasis). In one long-term study comparing adjuvant radiotherapy to usual care, both MFS and OS outcomes were significantly improved with radiotherapy, suggesting a relationship between these two endpoints. Four additional studies examined the association between MFS and OS. One study reported that distant metastasis at three years met the Prentice criteria for surrogacy of prostate cancer-specific survival at 10 years. A second study reported that MFS was one of four independent prognostic variables for OS in prostate cancer. The remaining two studies demonstrated that time to metastasis was significantly associated with prostate cancer-specific mortality. ConClusions: MFS has been used as the primary endpoint in several prostate cancer studies, providing support for the clinical relevance of this outcome. Current evidence from the literature suggests an association between MFS and OS, however additional research is needed to further investigate this relationship. Basel, Switzerland, 2 IMS Health Consulting, Brussels, Belgium, 3 Health Economics and Outcomes Research Ltd, Monmouth, UK objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and validated decision support tool. The model uses UKPDS68 and UKPDS82 risk equations (REs) to predict events and has been updated to include REs from the Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-Risk-Engine (A-RE). The objective of this study was to compare and contrast cardiovascular (CV) incidence and cost-effectiveness (CE) across these four REs. Methods: Lifetime analyses comparing the CE of metformin+ sulphonylurea (M+S) versus metformin + DPP-4 (M+D) was undertaken using the CDM. Basal insulin rescue therapy (BI) was applied to both arms at HbA1c threshold levels of 7.5%. Efficacy data for dual therapy was sourced from a published mixed treatment comparison; HbA1c and BMI change at one-year of -0.8% and 0.199kg/m2 (M+D);-0.79% and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, were applied. Hypoglycemia rates were taken from the same systematic review. US 2012 costs were used and discounting was applied at 3.0%. Results: In the base analysis (UKPDS68) predicted CV incidence for myocardial infarction, stroke, ischemic heart disease and heart failure was 31.42%, 15.59%, 12.85% and 21.01%, respectively, for patients treated with M+D and 31.39% , 15.23%, 12.51% and 21.26% for patients treated with M+S. This compared to 26.72%, 14.31%, 17.96% and 12.74% (M+D) and 26.02%, 13.94%, 17.91% and 13.43% (M+S) using UKPDS82 REs; 30.19%, 52.93%, 6.42% and 6.22% (M+D) and 29.7%, 53.98%, 6.23% and 6.5% (M+S) using S-NDR REs and 42.62%, 15.05%, 11.98% and 19.56% (M+D) and 42.17%, 15.1%, 11.97% and 20.46% (M+S) using A-RE REs. Incremental cost per quality adjusted life years were estimated at $78,537 (UKPDS68); $77,594 (UKPDS82); $70,054 (S-NDR) and $74,783 (A-RE). ConClusions: There was a noteworthy difference in predicted CV incidence across the four equations; however, CE results were relatively stable. Consequently, choice of RE appears unlikely to significantly impact CE. objeCtives: Evaluate for the first time in Brazil the pertinence of systematically requesting whole-body bone scintigraphy in early-stage HCC adult patients as a requisite for inclusion on the waiting list for HTx from a deceased donor, according to a reference center in South Brazil. Current pre-transplantation evaluation policy includes mandatory bone scintigraphy as a requisite for selecting patients to be included on hepatic transplantation list. Previous studies, however, have shown that routine scintigraphy is not cost-effective and generates unnecessary Health System costs. Methods: We retrospectively analyzed 256 medical files of early-stage HCC patients who underwent hepatic transplantation, 187 of whom were subjected to pre-transplantation bone scintigraphy. The most common etiology was hepatitis C viral infection, the most common liver functional class was Child B, and 78% of the patients met the Milan criteria. None of the 187 scintigraphies was positive for metas-
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